Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/13/2024 | Outperform → Mkt Perform | William Blair | |
10/14/2021 | $18.00 → $12.00 | Market Outperform | JMP Securities |
10/13/2021 | Outperform → Mkt Perform | William Blair | |
10/13/2021 | Buy → Neutral | BTIG |
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS as the first and only TMS treatment cleared as a first-line add-on for adolescents aged 15-21. The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA l
The Dow Jones index closed higher by around 80 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. PodcastOne The Trade: PodcastOne, Inc. (NASDAQ:PODC) Director D Jonathan Merriman bought a total of 42,000 shares at an average price of $1.95. To acquire these shares, it cost around $81,700. What's Happening: On June 6, Litchfield Hills ana
MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC:GBNHF) ("Greenbrook") today announced that they have entered into a definitive arrangement agreement (the "Definitive Agreement") in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. "This transaction brings together two of the leaders in the mental health space in the U.S., which will allow us to provide access to innovative care to patients suffering from mental health conditions. Leveraging the significant scale and capabilities of the two businesses, we can drive increased awareness of Neur
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024. Second Quarter 2024 Highlights Second quarter 2024 revenue of $16.5 million, a 7% decrease as compared to the second quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4 million in the quarter, representing 50 systemsU.S. treatment session revenue decreased by 5% ve
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/xsxbsaxh. To listen to the conference call on your telephone, participants may register f
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar® patient data management software, introducing a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecurity. "With the latest upgrades, we're not just enhancing technology; we're transforming the way practices can care for patients," said Cory Anderson, SVP of R&D and Clinical. "The new
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is proud to shine a light on the powerful stories shared through the NeuroStar Voices Portal in recognition of Suicide Prevention Month. Launched last year, the portal has become a vital platform for individuals to share their journeys of battling depression and reclaiming their lives through NeuroStar Advanced Therapy. NeuroStar is also marking a key milestone, reaching halfway toward its goal of saving 3,325 lives with this transformative
MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, proudly announces the two-year anniversary of NeuroStar University (NSU). This milestone will be celebrated with a special event held at the NSU training center in Charlotte, North Carolina, showcasing the profound impact of NSU's pioneering training programs on pioneering new standards in patient care and responsiveness. "NeuroStar University is a key part of our ongoing commitment to supporting our healthcare providers. The skills they gai
PREM14A - Neuronetics, Inc. (0001227636) (Filer)
DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
William Blair downgraded Neuronetics from Outperform to Mkt Perform
JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously
William Blair downgraded Neuronetics from Outperform to Mkt Perform